Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

LS Chang, R Barroso-Sousa, SM Tolaney… - Endocrine …, 2019 - academic.oup.com
Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

[HTML][HTML] Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review

JW Hommes, RJ Verheijden, KPM Suijkerbuijk… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of patients
with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA …

[HTML][HTML] Hypertension in thyroid disorders

E Berta, I Lengyel, S Halmi, M Zrínyi, A Erdei… - Frontiers in …, 2019 - frontiersin.org
Arterial hypertension represents a major global health concern; more than one fourth of the
population is affected by high blood pressure. Albeit the underlying cause of the disease …

[HTML][HTML] Holistic approach to immune checkpoint inhibitor-related adverse events

R Poto, T Troiani, G Criscuolo, G Marone… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

[HTML][HTML] Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside

L Wu, VHM Tsang, SC Sasson, AM Menzies… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at
the price of a new array of immune related adverse events. Among these is β-cell failure …

Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer

CA Muir, AM Menzies, R Clifton-Bligh, VHM Tsang - Thyroid, 2020 - liebertpub.com
Background: Inhibitory antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the …

[HTML][HTML] Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities

J Taylor, A Gandhi, E Gray, P Zaenker - Frontiers in immunology, 2023 - frontiersin.org
The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented
treatment benefits being obtained for cancer patients, including improved patient survival …

[HTML][HTML] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

H Matsuoka, T Hayashi, K Takigami, K Imaizumi… - Bmc Cancer, 2020 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death
protein 1 (PD-1) are used for the treatment of various cancer types. However, immune …

Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities

RS Goodman, S Jung, JM Balko… - Immunological …, 2023 - Wiley Online Library
Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …

[HTML][HTML] Adverse effects of anti-PD-1/PD-L1 therapy in non-small cell lung cancer

C Su, H Wang, Y Liu, Q Guo, L Zhang, J Li… - Frontiers in …, 2020 - frontiersin.org
Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal
antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging …